Bupivacaine liposome is one of 49 small molecule programs targeting Cognitive Disorder. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
24 competitors in Postoperative Analgesia
Precedex
Duragesic
Decadron
Nubain
Celebrex
EXPAREL
Intrathecal Morphine
Bupivacaine Only
Advil
Bupivacaine liposome
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details